Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 25;64(1):2301504.
doi: 10.1183/13993003.01504-2023. Print 2024 Jul.

Diagnostic delay and access to care in bronchiectasis: data from the EMBARC/ELF patient survey

Arietta Spinou  1   2 , Marta Almagro  3 , Bridget Harris  3 , Jeanette Boyd  4 , Tove Berg  3 , Beatriz Herrero-Cortina  5   6 , Annette Posthumous  3 , Stefano Aliberti  7 , Barbara Crossley  3 , Thomas F Ruddy  3 , Nili Stein  8 , Megan L Crichton  9 , Pieter C Goeminne  10 , James D Chalmers  9 , Michal Shteinberg  11
Affiliations

Diagnostic delay and access to care in bronchiectasis: data from the EMBARC/ELF patient survey

Arietta Spinou et al. Eur Respir J. .

Abstract

The EMBARC/ELF patient survey shows a need for increasing the availability of and access to expert bronchiectasis care and services https://bit.ly/3QTWY0E

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: B. Harris and A. Posthumous are patients with bronchiectasis and members of the European Lung Foundation (ELF) Bronchiectasis Patient Advisory Group; this is an unpaid, voluntary role. J. Boyd is an employee of ELF. B. Herrero-Cortina reports payment or honoraria for lectures, presentations, manuscript writing or educational events from SEPAR (Spanish Respiratory Society). B. Crossley is a voluntary member of the ELF Bronchiectasis Patient Advisory Group. M.L. Crichton reports consultancy fees from Boxer Capital LLC. J.D. Chalmers has received research grants from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Gilead Sciences, Grifols, Novartis, Insmed and Trudell; and received consultancy or speaker fees from Antabio, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Insmed, Janssen, Novartis, Pfizer, Trudell and Zambon. M. Shteinberg reports grants from GSK and Novartis, personal fees from Boehringer Ingelheim, GSK, Novartis, AstraZeneca, Kamada, Teva, GSK, Zambon, Airphysio, Bonus Biogroup and Syncrony Medical, and non-financial support from GSK, Boehringer Ingelheim, Actelion, GSK and Rafa. The remaining authors have no potential conflicts of interest to disclose.

References

    1. Chalmers JD, Aliberti S, Altenburg J, et al. . Transforming clinical research and science in bronchiectasis: EMBARC3, a European Respiratory Society Clinical Research Collaboration. Eur Respir J 2023; 61: 2300769. doi:10.1183/13993003.00769-2023 - DOI - PubMed
    1. Chalmers JD, Goeminne P, Aliberti S, et al. . The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med 2014; 189: 576–585. doi:10.1164/rccm.201309-1575OC - DOI - PMC - PubMed
    1. Polverino E, Goeminne PC, McDonnell MJ, et al. . European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J 2017; 50: 1700629. - PubMed
    1. Hill AT, Sullivan AL, Chalmers JD, et al. . British Thoracic Society Guideline for bronchiectasis in adults. Thorax 2019; 74: Suppl. 1, 1–69. - PubMed
    1. Martínez-García M, Máiz L, Olveira C, et al. . Spanish guidelines on treatment of bronchiectasis in adults. Arch Bronconeumol (Engl Ed) 2018; 54: 88–98. doi:10.1016/j.arbr.2017.07.014 - DOI - PubMed

LinkOut - more resources